We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IDEXX (IDXX) Stock Up 18.4% YTD: Will the Rally Continue?
Read MoreHide Full Article
IDEXX Laboratories, Inc.‘s (IDXX - Free Report) shares have surged 18.4% year to date compared with the industry’s increase of 8.6%. The Medical sector has declined 1.3% in the said time frame. The company has a market capitalization of $40.09 billion.
The continued solid demand for veterinary services and benefits from strong IDEXX execution and expanded global premium instrument placements continue to drive this Zacks Rank #3 (Hold) company. Its earnings increased 18.9% in the last five years, better than the industry average of 4.2%.
IDEXX’s ROE for the trailing 12 months was 117.4%, better than the industry average of (34.9%). It has a Growth Score of B. The Growth Score analyzes the growth prospects for a company and also evaluates its corporate financial statements.
Will the Upside Continue?
The Zacks Consensus Estimate for IDEXX’s 2023 earnings is pegged at $9.65, indicating a 20.2% increase from the year-ago reported figure. The consensus estimate for 2023 revenues is pegged at $3.66, indicating a year-over-year improvement of 8.6%.
IDEXX’s strong global performance represents major growth catalyst. International revenues in the first quarter were aided by a gain in CAG and Water businesses. Globally, IDEXX achieved strong organic revenue growth across its modalities in the said quarter. The year-on-year growth on global premium instrument installed base reflecting double-digit increases across Catalyst, Premium Hematology and SediVue platforms is expected to boost the company’s performance in coming quarters.
CAG premium instrument placements increased 3% in the first quarter. The quality of instrument placements continues to be excellent, reflecting a 7% growth in new and competitive Catalyst placements. ProCyte One momentum also continues to be strong globally, reflecting on a global installed base that more than doubled over the last year to 9,400 units.
Image Source: Zacks Investment Research
The solid CAG Diagnostics recurring revenue growth continues to be a key growth driver for the company, supported by global net price gains. Solid U.S. volume growth is also expected to be supported by new business gains, high customer retention levels and continued increases in diagnostic frequency and utilization at the practice level.
International CAG Diagnostics’ recurring revenue gains were supported by strong IDEXX execution. Higher net price realization, sustained new business gains and a double-digit expansion of premium instrument installed base are other tailwinds.
The raised 2023 guidance is an indicator of continued future growth. For 2023, the company expects revenue growth in the range of $3.615-$3,700, indicating growth of 7.5-10% on a reported and organic basis (up from the previous guidance of $3,590-$3,690 million). The Zacks Consensus Estimate for the same is currently pegged at $3.63 billion.
IDEXX’s full-year earnings per share guidance is now pegged in the range of $9.33-$9.75, indicating a rise of 16-21% on a reported basis (up from the previous guidance of $9.27-$9.75). The Zacks Consensus Estimate for full-year earnings per share is currently pegged at $9.61.
Estimate Trends
The Zacks Consensus Estimate for IDXX’s 2023 and 2024 has moved 0.7% and 5.2% north, respectively, in the past 90 days that indicate analyst’s optimism.
Key Picks
Some better-ranked stocks in the broader medical space are CONMED (CNMD - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
CONMED, carrying Zacks Rank# 2 (Buy), has an estimated long-term growth rate of 19.4%. The company’s earnings surpassed estimates in two of the trailing four quarters, missed once and met in another, delivering a negative average surprise of 10.54%.
Merit Medical, currently carrying a Zacks Rank #2, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 20.2%.
Merit Medical has improved 60.2% compared with the industry’s 24.2% growth in the past year.
Boston Scientific, presently holding a Zacks Rank #2, has an estimated long-term growth rate of 11.5%. BSX’s earnings surpassed estimates in two of the trailing four quarters and missed twice, the average surprise being 1.9%.
Boston Scientific has gained 50.8% against the industry’s 18.1% decline in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
IDEXX (IDXX) Stock Up 18.4% YTD: Will the Rally Continue?
IDEXX Laboratories, Inc.‘s (IDXX - Free Report) shares have surged 18.4% year to date compared with the industry’s increase of 8.6%. The Medical sector has declined 1.3% in the said time frame. The company has a market capitalization of $40.09 billion.
The continued solid demand for veterinary services and benefits from strong IDEXX execution and expanded global premium instrument placements continue to drive this Zacks Rank #3 (Hold) company. Its earnings increased 18.9% in the last five years, better than the industry average of 4.2%.
IDEXX’s ROE for the trailing 12 months was 117.4%, better than the industry average of (34.9%). It has a Growth Score of B. The Growth Score analyzes the growth prospects for a company and also evaluates its corporate financial statements.
Will the Upside Continue?
The Zacks Consensus Estimate for IDEXX’s 2023 earnings is pegged at $9.65, indicating a 20.2% increase from the year-ago reported figure. The consensus estimate for 2023 revenues is pegged at $3.66, indicating a year-over-year improvement of 8.6%.
IDEXX’s strong global performance represents major growth catalyst. International revenues in the first quarter were aided by a gain in CAG and Water businesses. Globally, IDEXX achieved strong organic revenue growth across its modalities in the said quarter. The year-on-year growth on global premium instrument installed base reflecting double-digit increases across Catalyst, Premium Hematology and SediVue platforms is expected to boost the company’s performance in coming quarters.
CAG premium instrument placements increased 3% in the first quarter. The quality of instrument placements continues to be excellent, reflecting a 7% growth in new and competitive Catalyst placements. ProCyte One momentum also continues to be strong globally, reflecting on a global installed base that more than doubled over the last year to 9,400 units.
The solid CAG Diagnostics recurring revenue growth continues to be a key growth driver for the company, supported by global net price gains. Solid U.S. volume growth is also expected to be supported by new business gains, high customer retention levels and continued increases in diagnostic frequency and utilization at the practice level.
International CAG Diagnostics’ recurring revenue gains were supported by strong IDEXX execution. Higher net price realization, sustained new business gains and a double-digit expansion of premium instrument installed base are other tailwinds.
The raised 2023 guidance is an indicator of continued future growth. For 2023, the company expects revenue growth in the range of $3.615-$3,700, indicating growth of 7.5-10% on a reported and organic basis (up from the previous guidance of $3,590-$3,690 million). The Zacks Consensus Estimate for the same is currently pegged at $3.63 billion.
IDEXX’s full-year earnings per share guidance is now pegged in the range of $9.33-$9.75, indicating a rise of 16-21% on a reported basis (up from the previous guidance of $9.27-$9.75). The Zacks Consensus Estimate for full-year earnings per share is currently pegged at $9.61.
Estimate Trends
The Zacks Consensus Estimate for IDXX’s 2023 and 2024 has moved 0.7% and 5.2% north, respectively, in the past 90 days that indicate analyst’s optimism.
Key Picks
Some better-ranked stocks in the broader medical space are CONMED (CNMD - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
CONMED, carrying Zacks Rank# 2 (Buy), has an estimated long-term growth rate of 19.4%. The company’s earnings surpassed estimates in two of the trailing four quarters, missed once and met in another, delivering a negative average surprise of 10.54%.
CNMD’s shares have risen 53.8% in the past year compared with the industry’s 24.2% growth. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Merit Medical, currently carrying a Zacks Rank #2, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 20.2%.
Merit Medical has improved 60.2% compared with the industry’s 24.2% growth in the past year.
Boston Scientific, presently holding a Zacks Rank #2, has an estimated long-term growth rate of 11.5%. BSX’s earnings surpassed estimates in two of the trailing four quarters and missed twice, the average surprise being 1.9%.
Boston Scientific has gained 50.8% against the industry’s 18.1% decline in the past year.